Regression of hypertensive left ventricular hypertrophy by Losartan compared with atenolol: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial
Academic Article
Overview
MeSH Major
Adrenergic beta-Antagonists
Angiotensin II Type 1 Receptor Blockers
Atenolol
Hypertension
Hypertrophy, Left Ventricular
Losartan
abstract
Antihypertensive treatment with losartan, plus hydrochlorothiazide and other medications when needed for pressure control, resulted in greater LVH regression in patients with ECG LVH than conventional atenolol-based treatment. Thus, angiotensin receptor antagonism by losartan has superior efficacy for reversing LVH, a cardinal manifestation of hypertensive target organ damage.
